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Objectives. We sought to determine the use and association with
30-day mortality of intravenous heparin for the treatment of acute
myocardial infarction in elderly patients not treated with a reperfu-
sion strategy and without contraindications to anticoagulation.
Background. The benefit of using full-dose intravenous heparin
for the treatment of acute myocardial infarction in the elderly is
not known.
Methods. We conducted a retrospective cohort study using
hospital medical records of all Medicare beneficiaries admitted to
the hospital with an acute myocardial infarction in Alabama,
Connecticut, Iowa and Wisconsin from June 1992 through Febru-
ary 1993.
Results. Among the 6,935 patients >265 years old who had no
absolute chart-documented contraindications to heparin, 3,227
(47%) received early full-dose intravenous heparin therapy. After
adjustment for baseline differences in demographic, clinical and
treatment factors between patients with and without heparin, the
use of heparin (odds ratio 1.02, 95% confidence interval 0.87 to
1.18) was not associated with a significantly better 30-day mor-
tality rate.
Conclusions. Although intravenous heparin was commonly used
for treatment of acute myocardial infarction in the elderly, it was not
associated with an improved 30-day mortality rate. Although the
findings of this observational study must be interpreted with care,
they lead us to question whether the prevalent use of intravenous
heparin has therapeutic effectiveness in this population.
(J Am Coll Cardiol 1998;31:973–9)
©1998 by the American College of Cardiology
Despite the widespread use of intravenous heparin for the
treatment of acute myocardial infarction (1), its value in this
setting is controversial (2), especially among patients who do
not receive a primary reperfusion strategy. Early trials of
full-dose heparin supported its use for the treatment of acute
myocardial infarction, but they were conducted before the
routine use of aspirin and included very few elderly patients
(3–5). A recent systematic overview of 26 randomized trials of
anticoagulant therapy for suspected acute myocardial infarc-
tion concluded that the clinical evidence does not justify the
routine use of heparin in the treatment of acute myocardial
infarction (6). The American College of Cardiology/American
Heart Association (ACC/AHA) guidelines (7) for the treat-
ment of acute myocardial infarction state that, “in patients who
will not be given thrombolytic therapy, there is little evidence
about the benefit of heparin in the modern era, in which
aspirin, [beta]-adrenoceptor blockers, nitrates and ACE
[angiotensin-converting enzyme] inhibitors are routinely avail-
able.” The guidelines do not endorse the use of full-dose
intravenous heparin for the treatment of patients who do not
receive a primary reperfusion strategy.
We sought to examine the use and effectiveness of heparin
in clinical practice among elderly patients with an acute
myocardial infarction. To address this issue, we made use of a
population-based, observational study design that included a
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retrospective review of the complete hospital medical records
for Medicare beneficiaries admitted to the hospital with an
acute myocardial infarction in Alabama, Connecticut, Iowa
and Wisconsin from June 1992 through February 1993. We
focused on patients who had no contraindication for anticoag-
ulation and were not treated with a primary reperfusion
strategy.
Methods
Study sample. The study sample was derived from the
Cooperative Cardiovascular Project (CCP) pilot, a Health
Care Financing Administration (HCFA) initiative to improve
the quality of care for Medicare beneficiaries with acute
myocardial infarction (8). The sample included patients $65
years old with a principal discharge diagnosis of acute myocar-
dial infarction [International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM 410)] (9) in Ala-
bama, Connecticut, Iowa, and Wisconsin between June 1, 1992
and February 28, 1993. We excluded admissions that were not
related to the care of an acute myocardial infarction (the fifth
digit of the ICD-9-CM code 5 2) and other patients who did
not have evidence of an acute myocardial infarction as docu-
mented by a peak creatine kinase, MB fraction (CK-MB) .5%
or lactic dehydrogenase (LDH)-2 .1.5 times the normal value
and LDH-1 . LDH-2 or two of the three following criteria:
chest pain, a twofold elevation of CK or new Q waves on the
electrocardiogram (ECG). We excluded admissions in which
patients were transferred from another acute care institution
because the focus of this study was the treatment of acute
myocardial infarction on initial presentation. For patients with
more than one admission during the study period, we only
included the first admission.
We restricted the cohort to patients who did not have a
contraindication to heparin therapy and had no documented
reason to receive limited treatment. Therefore, we excluded
patients with active bleeding, a history of hemorrhagic stroke,
a history of a bleeding disorder, thrombocytopenia (platelets
,100,000), anemia (hematocrit ,30% or hemoglobin ,10
mg/dl), rectal bleeding, a prothrombin time .16 s, recent head
trauma or allergy to heparin. We also excluded patients if the
medical record documented that they were terminally ill or had
metastatic cancer, if the admission orders indicated that the
patient should be given palliative care only or if a “do-not-
resuscitate” order was written at the time of admission. To
focus on patients who did not receive a primary revasculariza-
tion strategy, we excluded patients who received thrombolytic
therapy or underwent primary percutaneous coronary revascu-
larization within the first 24 h.
Collection of data. The medical records for each admission
were obtained from the acute care hospitals. Trained nurses
and medical record technicians abstracted the hospital medical
record and entered the information directly into a computer-
ized database management system using the Uniform Clinical
Data Set System (10). On-line data definitions and range
checks were used to decrease errors and data entry variability.
We reabstracted 594 charts to test the reliability of the data
collection; for heparin received during the hospital stay, the
kappa value was 0.94. The initial ECG for each patient in the
Connecticut cohort was interpreted by a trained physician
(J.M.) who was not aware of the study hypothesis. The medical
charts of the Connecticut cohort were also reabstracted to
determine the highest activated partial thromboplastin time
(aPTT) within 24 h of the initiation of therapy. The source of
the mortality data was the Medicare Beneficiary Record. This
information is obtained from the Social Security Administra-
tion and is considered highly accurate.
Variables. Patients were classified in the heparin group if
they received intravenous heparin within the first 2 hospital
days. The 2-day period was chosen to allow for the possibility
that some patients might have presented late on the day of
admission and received heparin the next day after presenta-
tion. We also repeated the study after classifying patients in the
heparin group only if the medication was initiated on the day
of presentation. We did not consider patients to be in the
heparin therapy group if they received heparin subcutaneously
or received a dose more appropriate for prophylaxis of venous
thrombosis (#10,000 U/day) than systemic anticoagulation.
To evaluate the use and effectiveness of heparin we made
use of the following variables: age, gender, race, medical
history (hypertension, diabetes, smoking, myocardial infarc-
tion, congestive heart failure, coronary revascularization,
stroke), medications on admission (beta-adrenergic blocking
agents, digoxin, loop diuretic drugs), vital signs on admission
(pulse, systolic blood pressure, respiratory rate), clinical con-
dition on admission (congestive heart failure, renal dysfunc-
tion, shock, intubation and cardiac arrest) and cointerventions
on admission (treatment with thrombolytic therapy or beta-
blockers). Systolic blood pressure, pulse and respiratory rate
were taken as the highest value recorded within 24 h after
admission. Renal dysfunction was defined as blood urea nitro-
gen .40 mg/dl or creatinine .2.5 mg/dl. Of these variables,
data were missing in ,3% of cases. We evaluated these
variables for collinearity and determined that the correlation
between any pair of variables was ,0.3.
ECG variables abstracted by a physician were also available
Abbreviations and Acronyms
ACC/AHA 5 American College of Cardiology/American Heart
Association
aPTT 5 activated partial thromboplastin time
CCP 5 Cooperative Cardiovascular Project
CI 5 confidence interval
CK 5 creatine kinase
ECG 5 electrocardiogram, electrocardiographic
HCFA 5 Health Care Financing Administration
ICD-9-CM 5 International Classification of Diseases, Ninth
Revision, Clinical Modification
LDH 5 lactic dehydrogenase
OR 5 odds ratio
974 KRUMHOLZ ET AL. JACC Vol. 31, No. 5
HEPARIN FOR AMI IN THE ELDERLY April 1998:973–9
only for the Connecticut cohort (n 5 1,573). ECG variables in
the Connecticut cohort were derived from the initial ECG and
included the presence of ST segment elevation ($2 mm in at
least two contiguous leads) or Q waves not known to be old
and the presence of left bundle branch block.
The principal end point for the outcome analysis was 30-day
mortality. We also evaluated in-hospital hemorrhage, in-
hospital transfusion, in-hospital strokes and 1-year mortality.
Statistical analysis. We evaluated the association of the
use of heparin with demographic characteristics (age, gender
and race), clinical characteristics (coronary artery disease risk
factors, past medical history, admission cardiac medications,
cardiac history, acuity of presentation, ECG presentation) and
cointerventions (aspirin and beta-blockers). Then, using the
variables from the bivariate analysis, we developed a multiva-
riable logistic regression model by backward stepwise selection
with the use of heparin as the dependent variable. Variables
were dropped from the model at a significance level of p ,
0.01.
Next, we determined whether the use of heparin was
associated with better 30-day survival, after adjusting for
potential confounders. To accomplish this objective, we devel-
oped a series of logistic regression models to predict 30-day
mortality using the patients who did not receive heparin as the
reference group. Demographic variables, clinical variables and
cointerventions (beta-blockers, thrombolytic therapy) were
added in sequential steps. For each model we calculated an
odds ratio and a 95% confidence interval for patients who
received heparin compared with those who did not. We also
checked for interactions between heparin and the use of
aspirin, the patient’s age, the presence of heart failure, the
presence of diabetes mellitus, the history of an acute myocar-
dial infarction and the presence of chest pain, respectively.
Goodness of fit was evaluated by comparing fitted proba-
bilities of 30-day mortality with observed 30-day mortality
within deciles of risk and calculating the corresponding ob-
served chi-square statistics (11). In addition, we calculated an
area under the receiver operator curve for each model to
evaluate the discriminating power of the fitted model (12).
To determine whether our results were sensitive to changes
in our definition of the study sample or the timing of treat-
ment, we repeated the final analysis after restricting the
heparin group to those patients who had treatment initiated on
the day of admission. We also repeated the mortality models
with the Connecticut cohort, adding ECG variables that are
only available in the Connecticut database to the final models.
These variables, the presence of ST segment elevation and left
bundle branch block were selected because they were known to
be associated with 30-day mortality and were possible sources
of residual confounding in the main analysis. Finally, we
repeated the fully adjusted model to evaluate the association
between the use of heparin and 1-year mortality.
Our sample size was fixed by the size of the CCP pilot. We
calculated that we would have .90% power to detect a
three-point difference (15% vs. 18%) in 30-day mortality based
on the sample.
All calculations were performed using the software system
STATA 5.0.
Results
Study sample. The study sample included 6,935 patients
(Table 1). The study sample was elderly (mean age 76.3 6 7.2
years) and had roughly equal proportions of men (52%) and
women (48%).
Use of heparin. Among the patients in the study sample,
3,227 (47%) received full-dose intravenous heparin within the
first 2 hospital days. The nonrandom allocation of patients
among treatment groups is demonstrated by significant differ-
ences in the demographic and clinical characteristics among
the two groups (Table 2). The patients who received heparin
had a more favorable clinical profile as evidenced by their
younger age, more favorable clinical history (lower prevalence
of congestive heart failure, diabetes, stroke, chronic obstruc-
tive pulmonary disease, peptic ulcer disease, renal insuffi-
ciency, preadmission use of calcium-channel blocking agents,
digoxin, angiotensin-converting enzyme inhibitors, loop di-
uretic drugs), better admission characteristics (lower preva-
lence of tachycardia, tachypnea, hypotension, intubation) and
higher use of beta-blockers and aspirin. In the multivariable
analysis (Table 3), the following variables were independently
associated with the use of heparin: age, gender, comorbidity
(stroke, chronic obstructive pulmonary disease, renal dysfunc-
tion), preadmission medications (digoxin, beta-blockers), his-
tory of percutaneous transluminal coronary angioplasty, pres-
ence and duration of chest pain and treatment with aspirin.
Table 1. Study Sample
No. of
Subjects
Total sample 16,182
AMI confirmed 13,655
Exclusions*
Age ,65 yr 916
Transfer in/from emergency room 2,346
Terminal illness, metastatic cancer, recent trauma 1,218
PTCA within 6 h of admission 259
Thrombolytic therapy on admission 1,170
Heparin dose 547
Repeat admission 1,164
Total exclusions 7,744
Contraindications
History of hemorrhagic stroke 21
Active bleeding at admission 94
Rectal blood 67
Allergy to heparin 4
History of bleeding disorder 37
Thrombocytopenia 57
Anemia 384
Prothrombin time .16 s 297
Study sample 6,935
*Categories can be mutually exclusive. AMI 5 acute myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty.
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The Connecticut cohort of the CCP pilot was used to
evaluate whether heparin treatment achieved effective antico-
agulation. Of the patients in whom intravenous heparin was
started, 88% had an aPTT .46 s within 24 h of the initiation
of therapy.
Complications. The use of heparin was associated with an
increased risk of complications. The rate of a major hemor-
rhage during the hospital stay was higher among patients who
received heparin than in those who did not (2.8% vs. 1.3%, p ,
0.001). The rate of transfusions was also higher in patients who
received heparin (11.6% vs. 5.6%, p , 0.001). The number of
strokes was slightly higher in the heparin group (1.7% vs. 1.3%,
p 5 0.2).
Mortality. The 30-day mortality rate for the entire study
sample was 16.2% (1,121 of 6,935). The 30-day mortality rate
for the patients who received heparin was 13.4% (431 of 3,227)
compared with 18.6% (690 of 3,708, p , 0.001) for those who
did not receive heparin. To adjust for the baseline differences
in risk, a sequence of multivariate logistic regression models
was developed to test the association of the treatment groups
and survival (Table 4).
In the model that adjusted for demographic and clinical
variables, patients who received heparin did not demonstrate a
significantly lower odds of 30-day mortality (odds ratio [OR]
0.92, 95% confidence interval [CI] 0.80 to 1.07). After adding
variables indicating the use of aspirin and beta-blockers, the
patients who received heparin (OR 1.02, 95% CI 0.87 to 1.18)
did not have a significantly lower odds of 30-day mortality than
those who did not receive heparin. In this model, aspirin was
associated with a significantly lower odds of 30-day mortality
(OR 0.67, 95% CI 0.58 to 0.78). There was no evidence of a
significant interaction between heparin and use of aspirin,
patient age, presence of heart failure, presence of diabetes
mellitus, history of an acute myocardial infarction and pres-
ence of chest pain, respectively. Heparin was not associated
Table 3. Factors Associated With Use of Heparin for Acute
Myocardial Infarction, Based on Multiple Logistic Regression With
Backward Stepwise Selection*
Factor OR (95% CI) p Value
Age 75–84 yr 0.67 (0.60–0.75) , 0.001
Age $ 85 yr 0.43 (0.36–0.50) , 0.001
Female gender 0.80 (0.72–0.89) , 0.001
Hx of PTCA 1.28 (1.02–1.60) 0.03
Stroke 0.78 (0.66–0.92) , 0.01
COPD 0.85 (0.73–0.99) 0.04
Chest pain present 2.04 (1.77–2.34) , 0.001
Duration . 6 h 1.29 (1.10–1.51) , 0.01
Resp rate . 30 breaths/min 0.79 (0.69–0.92) , 0.002
Preadmission digoxin 0.82 (0.73–0.91) , 0.001
Preadmission BBs 1.86 (1.66–2.04) , 0.001
Renal insufficiency 0.72 (0.58–0.90) , 0.01
Aspirin 2.14 (1.92–2.38) , 0.001
Intubation 1.28 (1.01–1.61) 0.04
*Adjusted odds ratios (ORs) were derived from a multiple logistic regression
analysis in which each odds ratio was adjusted for all other factors listed; an odds
ratio ,1 indicates that patients with the characteristic have a lower likelihood of
receiving heparin than those without the characteristic; an odds ratio .1
indicates that patients with the characteristic have a higher likelihood of
receiving heparin than those without the characteristic. CI 5 confidence interval;
PTCA 5 percutaneous transluminal coronary angioplasty; other abbreviations as
in Table 2.
Table 2. Characteristics Associated With Patients Who Received
Heparin
Heparin
(n 5 3,227)
[no. (%) of pts]
No Heparin
(n 5 3,708)
[no. (%) of pts] p Value
Age group
65–74 yr 1,683 (52%) 1,339 (36%) , 0.001
75–84 yr 1,250 (39%) 1,679 (45%) , 0.001
$85 yr 294 (9%) 690 (19%) , 0.001
Female 1,404 (44%) 1,947 (53%) , 0.001
White 3,044 (94%) 3,433 (93%) , 0.01
Cardiac risk factor
Hx of HTN 1,724 (53%) 1,887 (51%) 0.04
DM 863 (27%) 1,081 (29%) 0.03
Current smoker 491 (15%) 483 (13%) 0.01
Cardiac Hx
MI 826 (26%) 973 (26%) 0.54
CHF 876 (27%) 1,420 (38%) , 0.001
Angioplasty 212 (7%) 160 (4%) , 0.001
Bypass surgery 450 (14%) 389 (10%) , 0.001
Medical comorbidity
Stroke 288 (9%) 455 (12%) , 0.001
COPD 384 (12%) 544 (15%) 0.001
Peptic ulcer disease 124 (4%) 167 (5%) 0.17
Renal insufficiency* 147 (5%) 319 (9%) , 0.001
Preadmission med
Aspirin 1,086 (34%) 1,035 (28%) , 0.001
Nitrates 1,058 (33%) 1,186 (32%) 0.48
BBs 584 (18%) 509 (14%) , 0.001
CCBs 1,046 (32%) 1,222 (33%) 0.63
Digoxin 877 (27%) 1,308 (35%) , 0.001
ACEI 503 (16%) 691 (19%) , 0.001
Loop diuretic 974 (30%) 1,381 (51%) , 0.001
Warfarin 128 (4%) 161 (4%) 0.44
Chest pain
Present 2,836 (88%) 2,663 (72%) , 0.001
Duration . 6 h 474 (15%) 344 (9%) , 0.001
Vital signs
Pulse .100 bpm 1,214 (38%) 1,667 (45%) , 0.001
Resp rate . 30
breaths/min
417 (13%) 730 (20%) , 0.001
SBP , 125 mm Hg 210 (7%) 287 (8%) 0.05
Shock within 24 h of
admission
22 (1%) 29 (1%) 0.63
Intubation within 24 h
of admission
148 (5%) 238 (6%) , 0.001
CPR 73 (2%) 136 (4%) , 0.001
Admission med
Aspirin 2,400 (74%) 1,941 (52%) , 0.001
BBs 1,277 (40%) 776 (21%) , 0.001
*Blood urea nitrogen .40 mg/dl or creatinine .2.5 mg/dl. ACEI 5
angiotensin-converting enzyme inhibitor; BBs 5 beta-blockers; bpm 5 beats/min;
CCBs 5 calcium channel blockers; CHF 5 congestive heart failure; COPD 5
chronic obstructive pulmonary disease; CPR 5 cardiopulmonary resuscitation;
DM 5 diabetes mellitus; HTN 5 hypertension; Hx 5 history; med 5 medica-
tion; MI 5 myocardial infarction; pts 5 patients; Resp 5 respiratory.
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with a survival benefit in any of these subgroups. The analyses
were repeated after restricting the heparin group to those
patients who received the medication on the first hospital day,
and there was no substantial change in the odds ratio (OR 0.96,
95% CI 0.82 to 1.12).
When data from the Connecticut cohort were used, heparin
was not associated with a survival benefit even if the analysis
was restricted to patients who had an aPTT .46 s within 24 h
of the initiation of therapy. Moreover, the addition of ST
segment elevation and left bundle branch block to the model
did not substantially change the result. Finally, using 1-year
mortality after admission as the outcome, heparin therapy was
not associated with a significant survival benefit (OR 1.04, 95%
CI 0.91 to 1.19).
Graphic displays of partial residual plots from these models
did not reveal any problems with our model assumptions. The
chi-square goodness of fit statistic for the final model with
demographic, clinical and treatment variables had a p value of
0.10, indicating that the fitted model was acceptable. Goodness
of fit statistics for models based on demographic variables only
and for demographic and clinical variables were also not
significant, indicating acceptable model fits. The final models
had areas under the receiver operating characteristic curves
that exceeded 75%, indicating good model discrimination.
Discussion
We report that heparin therapy is widely used for the
treatment of acute myocardial infarction in the vast majority of
elderly patients who are not treated with a primary reperfusion
therapy. However, we could not demonstrate that the use of
heparin was associated with a significantly lower 30-day mor-
tality, after adjusting for baseline differences in the treatment
groups. The present study supports the recommendations of
the ACC/AHA guidelines (7) and raises the possibility that the
widespread use of heparin (1) may not provide an important
benefit for elderly patients with an acute myocardial infarction.
Previous studies. The appropriate role of heparin for the
treatment of acute myocardial infarction is not well established
in the current era of treatment (2). Older studies have sug-
gested that heparin is associated with a 10% to 30% reduction
in short-term mortality after acute myocardial infarction
(13,14). However, these trials were performed before the
current era of treatment, leading experts to discount their
relevance to contemporary management (7).
Several more recent trials have evaluated the benefit of
heparin in the treatment of unstable angina and non-Q wave
myocardial infarction (15–20). Four trials found no significant
benefit of heparin beyond that provided by aspirin (15–17,19).
One study (18), by investigators from the Montreal Heart
Institute, reported that treatment with heparin was associated
with the development of significantly fewer myocardial infarc-
tions than treatment with aspirin. The Antithrombotic Therapy
in Acute Coronary Syndromes (ATACS) trial (20) found that
heparin and warfarin plus aspirin were more effective than
aspirin alone in the prevention of recurrent ischemic events in
the early phase of unstable angina.
A meta-analysis of these studies (21) has found that, when
taken together, there is a borderline significant trend toward a
benefit for patients treated with aspirin plus heparin compared
with those treated with aspirin alone. The relevance of these
trials to the current study is not clear. These studies focused
predominately on patients without an acute myocardial infarc-
tion, and few included substantial numbers of elderly patients.
Collins et al. (6) recently performed a systematic overview of
all 26 unconfounded randomized trials of anticoagulant ther-
apy for suspected acute myocardial infarction. They found that
heparin was only beneficial in this group in the absence of
aspirin therapy. They concluded that the clinical evidence from
the trials does not justify the routine use of heparin for the
treatment of suspected acute myocardial infarction.
Use of heparin. Despite the lack of evidence to support the
use of heparin, almost half of our cohort received it. These
findings are consistent with the report of the National Registry
of Myocardial Infarction (1), which found that .50% of
240,989 patients admitted to the hospital across the United
States with an acute myocardial infarction received intrave-
nous heparin. The frequent use of heparin highlights the need
for studies to determine whether this clinical strategy has
therapeutic effectiveness in the current era.
Our analysis also demonstrated the impact of the nonran-
dom allocation of patients to the various treatment groups.
Although the data do not reveal why physicians choose a
particular antithrombotic regimen, they do reveal certain
treatment patterns. Younger patients were much more likely to
have heparin included in their treatment regimen. The lowest
risk patients, based on admission characteristics, were most
likely to receive heparin. The difference in risk among the
treatment groups occurred even though patients with any
contraindication for heparin therapy or with a terminal illness
or preference for limitation of treatment had been excluded
from the analysis.
Table 4. Odds of 30-Day Mortality of Patients Treated With
Heparin Compared With Patients Not Treated With Heparin*
Heparin
Group
Unadjusted
Model
Adjusted Models
Demographic
Factors
Demographic
and Clinical
Factors
Demographic,
Clinical and
Treatment
Factors
OR 0.67 0.78 0.92 1.02
95% CI 0.59–0.77 0.68–0.89 0.80–1.07 0.87–1.18
*Demographic characteristics included age, gender, race; clinical character-
istics included preadmission use of aspirin, preadmission use of nitrates, pread-
mission use of beta-blockers, preadmission use of digoxin, preadmission use of
loop diuretic agents, history of diabetes, smoking, myocardial infarction, hyper-
tension, coronary revascularization, congestive heart failure, pulse .100 beats/
min, systolic blood pressure ,125 mm Hg, respiratory rate .30 breaths/min,
congestive heart failure on admission, shock on admission, resuscitation on
admission, intubation on admission, chest pain on admission, duration of chest
pain .6 h and renal dysfunction; treatment variables included admission use of
aspirin and beta-blockers. Abbreviations as in Table 3.
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Heparin and mortality. The observation that patient char-
acteristics were strongly related to the choice of heparin
therapy highlights the importance of using multivariable meth-
ods in the mortality analysis. With the more favorable clinical
profile of the heparin-treated patients, the unadjusted 30-day
mortality rate was lower. As expected, on the basis of the
bivariate analyses, the sequential adjustment for demographic,
clinical and treatment variables in the multivariable models
attenuated the decreased odds of 30-day mortality in the
heparin group. In the final model, patients who received
heparin did not have a significantly lower odds of 30-day
mortality. Although we cannot exclude the possibility that
unmeasured factors contributed to the appearance of no
difference between the groups, there is no indication that
heparin provided an important benefit to these patients.
To explore the possibility that heparin was providing a
benefit for a specific subgroup of patients, we evaluated the
interaction of heparin with aspirin, age and chest pain, respec-
tively. There was no significant interaction of heparin among
these subgroups. To further test our conclusions, we deter-
mined whether our results were sensitive to changes in the
definition of the study sample or in the length of follow-up.
None of these changes in the study sample affected our
principal finding.
Limitations and strengths. The most important limitation
of our observational study is the nonexperimental allocation of
treatment strategy. To address this issue, we restricted the
study sample to patients who were eligible for heparin therapy
and collected detailed clinical information from the medical
records to adjust for differences among the treatment groups in
their initial risk of 30-day mortality. We previously used these
methods in a similar study sample (22) to evaluate the associ-
ation of the acute use of aspirin and 30-day mortality and
found that the use of aspirin was associated with an adjusted
odds reduction in mortality of 22%, a figure that was very close
to the 23% odds reduction reported by the International Study
of Infarct Survival (ISIS)-2 trial.
In contrast, a major strength of our study is that it reflects
the experience of the entire spectrum of patients and hospitals
in four diverse states. This design avoids the problem of
selection bias by including the experience of hospitals outside
the sphere of the tertiary care hospitals, a class of institutions
that is disproportionately represented in published reports
(23). Our study design also has the strength of using data
abstracted from the hospital medical record, thereby avoiding
strict reliance on administrative data with its inherent limita-
tions (24).
Conclusions. This investigation was a result of a HCFA-
based initiative to improve health care for Medicare patients
admitted with acute myocardial infarction. We used data
developed within this initiative to evaluate the pattern of use
and therapeutic effectiveness of intravenous heparin for the
treatment of acute myocardial infarction. The data indicate
that more than half of elderly patients receive intravenous
heparin in the acute phase of admission for an acute myocar-
dial infarction. Our inability to find a mortality benefit associ-
ated with the use of heparin leads us to question the prevalent
belief that intravenous heparin has therapeutic effectiveness in
this population. These results suggest a need for more studies
to define the best antithrombotic regimen for selected groups
of elderly patients.
We are indebted to the members of the Peer Review Organizations from
Alabama, Connecticut, Iowa and Wisconsin and to all the other individuals,
hospitals and organizations who contributed to the development and implemen-
tation of the Cooperative Cardiovascular Project.
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